BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Institute of Biomedical Engineering (BME) - ECPv6.17.4.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Institute of Biomedical Engineering (BME)
X-ORIGINAL-URL:https://bme.utoronto.ca
X-WR-CALDESC:Events for Institute of Biomedical Engineering (BME)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220608T190000
DTEND;TZID=America/Toronto:20220608T200000
DTSTAMP:20220527T201730Z
CREATED:20220527T201730Z
LAST-MODIFIED:20220527T201730Z
UID:10000027-1654714800-1654718400@bme.utoronto.ca
SUMMARY:Special session with EngSci alumnus Dr. Amir Manbachi: Towards building a clinically oriented Ultrasound Hub—The journey of an EngSci immigrant to academia
DESCRIPTION:Dr. Amir Manbachi (EngSci 0T8\, BME MAsc 1T0\, PhD 1T5) founded the HEPIUS Innovation Lab\, focusing on the next generation of wearables and implantable medical ultrasound devices for spinal cord injury patients.  Join him for an interactive session where he’ll describe his journey from EngSci to his current position at Johns Hopkins University.
URL:https://bme.utoronto.ca/event/special-session-with-engsci-alumnus-dr-amir-manbachi-towards-building-a-clinically-oriented-ultrasound-hub-the-journey-of-an-engsci-immigrant-to-academia/
CATEGORIES:External Speaker Series
ATTACH;FMTTYPE=image/png:https://bme.utoronto.ca/wp-content/uploads/2022/05/Manbachi_June_2022.png
ORGANIZER;CN="Engineering Science":MAILTO:engsci@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220609T130000
DTEND;TZID=America/Toronto:20220609T150000
DTSTAMP:20220609T152227Z
CREATED:20220511T143904Z
LAST-MODIFIED:20220609T152227Z
UID:10000014-1654779600-1654786800@bme.utoronto.ca
SUMMARY:Spotlight on Clinical Translation: Making the leap from the lab bench to Phase I Clinical Trials
DESCRIPTION: \nJoin us for Spotlight on Clinical Translation: Making the leap from the lab bench to Phase I Clinical Trials\, hosted by The Stem Cell Network and Medicine by Design.\nThis workshop will provide investigators and trainees with a basic understanding of the clinical pipeline\, from essential pre-clinical studies to Phase I first in human trials. The invited speakers will review processes involved in clinical trial submission\, regulatory approval and product manufacturing. An interactive Q&A session will ensure participants can ask questions relevant to their research along with leveraging this opportunity to connect with clinical trial experts.\nClinical studies are a key element on the pathway of translational cell and gene therapies. It is\, therefore\, essential that principal investigators\, researchers\, trainees\, clinical research fellows and ecosystem partners working in Canada undertaking translational research have a thorough understanding of the clinical trial pipeline; focused specifically on the early phase clinical trial design processes.\nRegister now!\nRegistration deadline:\nAttendance at this event is limited; all those interested in participating must register by June 8\, 2022\, at 11:59 PM local time.\nView Agenda\n1:00-1:05 pm ET – Opening Remarks\nModerators: Harold Atkins and Darshan Brahmbhatt\n1:05-1:40 pm ET – Presentation by Natasha Kekre\, MD\, Hematologist\, The Ottawa Hospital Transplant and Cellular Therapy Program\, and Scientist\, Ottawa Hospital Research Institute\nPresentation title: Building the pre-CTA and CTA package for Phase I trials: Case study using CLIC CAR-T trial for relapsed/refractory CD19 positive hematologic malignancies\n1:45-2:10 pm ET – Presentation by Patrick Bedford\, MSc\, Managing Director\, weCANreg Consulting Group Inc.\nPresentation title: Leveraging a regulatory rerspective on your path to trials\n2:15-2:40 pm ET – Presentation by Linh Nguyen\, PhD\, Staff Scientist/Head\, Cell Manufacturing Team\, Tumor Immunotherapy Program\, Princess Margaret Cancer Centre\nPresentation title: Developing a cell manufacturing process for an early phase clinical trial\n2:40-2:45 pm ET – Break\n2:45-3:00 pm ET – General Discussion/Q&A session\n3:00 pm ET – Closing Remarks\nSpeaker and Chair Details\nSPEAKERS\nPatrick BedfordNatasha KekreLinh NguyenPatrick Bedford\nPatrick Bedford\, MSc – Managing Director\, weCANreg Consulting Group Inc.\nPatrick Bedford is an experienced and certified regulatory professional who is focused on facilitating global regenerative medicine development. He founded & operates weCANreg Consulting Group Inc.\, which provides regulatory strategy\, interaction\, and submission services. Furthermore\, Patrick is VP of Regulatory & Development at Artisan Bio\, which is a CRISPR-enabled multiplex cell engineering company making precision immunotherapies. In his spare time\, he remains an active educator and contributor to regulatory policy development.\nPrior to incorporating his own company and leading regulatory strategy at Artisan Bio\, Patrick developed regulatory consulting services for a regenerative medicine Network Centre of Excellence; planned 2 Canadian CAR-T New Drug Submissions; and led teams at Health Canada responsible for developing guidance for biosimilars\, transplant material\, and cell & gene therapies. While leading these policy initiatives at Health Canada\, Patrick also supported their Therapeutic Products Classification Committee; chaired the Cells\, Tissues\, and Organs Classification Committee; and championed international harmonization initiatives.\nPatrick completed an Honours Bachelor of Health Sciences degree at the University of Western Ontario\, a Master’s degree in Bioethics and Health Law at the University of Otago\, a Regulatory Affairs Certificate from the Regulatory Affairs Professional Society\, and is pursuing his MBA at the Jack Welch Management Institute.\nNatasha Kekre\nNatasha Kekre\, MD – Hematologist\, The Ottawa Hospital Transplant and Cellular Therapy Program\, and Scientist\, Ottawa Hospital Research Institute \nDr. Natasha Kekre has been appointed to the Department of Medicine in the Division of Hematology\, within the Transplant and Cellular Therapy Program at The Ottawa Hospital\, effective October 2015. She is also an associate scientist within the Ottawa Hospital Research Institute and an associate professor of medicine at the University of Ottawa. She completed her Bachelor’s in Science at the University of Windsor then obtained her medical degree from the University of Ottawa. She then trained at the University of Ottawa in Internal Medicine and Hematology. She went on to do a fellowship in stem cell transplantation at Dana Farber Cancer Institute in Boston\, MA with a Masters in Public Health from Harvard University.\nHer research is focused on developing early phase clinical trials and moving home grown therapeutic strategies into patients. She collaborates with a number of local investigators and scientists in Ottawa\, studying hematologic malignancies and blood and marrow transplant recipients more specifically. She collaborates with scientists and physicians across Canada to build a Canadian CAR-T cell platform (chimeric antigen receptor T cells are immune cells engineered to kill cancer cells)\, bringing this exciting new therapy to Canadian patients. Her other clinical research interests include improving transplant related outcomes and projects with an epidemiologic focus\, including but not limited to decision modeling and meta-analyses.\nShe also participates with a number of cooperative groups in North America including the Center for International Blood and Marrow Transplant Research\, the Canadian Blood and Marrow Transplant Group\, the American Society of Hematology and the American Society for Transplant and Cellular Therapy.\nLinh Nguyen\nLinh Nguyen\, PhD – Staff Scientist/Head\, Cell Manufacturing Team\, Tumor Immunotherapy Program\, Princess Margaret Cancer Centre\nDr. Linh Nguyen has led the Cell Manufacturing Team of the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre since 2005. Dr. Nguyen obtained her PhD in Immunology at the University of Toronto and pursued postdoctoral studies at Harvard Medical School. Her interests include tumor immunology and immunotherapy. Her team has manufactured cell and gene therapy products for clinical trials such as tumor-infiltrating lymphocytes (TILs)\, dendritic cells and T cell receptor gene-engineered T cells. The team’s activities also include quality assurance\, quality control\, and preparation of regulatory submissions.  \nCHAIR\nHarold AtkinsDarshan H. BrahmbhattHarold Atkins\nHarold Atkins\, MD – Attending Physician\, The Ottawa Hospital Transplant and Cell Therapy Program\, and Scientist\, Ottawa Hospital Research Institute\nDr. Harry Atkins is a physician of The Ottawa Hospital Transplant and Cell Therapy Program\, an Associate Professor of Medicine at the University of Ottawa\, and a scientist in the Ottawa Hospital Research Institute’s Center for Innovative Cancer Research.\nHe received his Bachelor of Medical Science degree and Medical Degree from the University of Ottawa followed by a rotating internship year at the Victoria General Hospital in Victoria BC. Specialty training in Internal Medicine was done at the University of Ottawa. Clinical and research fellowships in Hematology\, Stem Cell Transplantation and Experimental Hematology followed at the University of Washington and at the Ontario Cancer Institute.\nHe specializes in hematopoietic stem cell transplantation and has spearheaded the use of stem cell transplantation for immune repair to treat patients with severe autoimmune diseases including multiple sclerosis\, scleroderma\, myasthenia gravis and others. The outcome of a trial using autologous hematopoietic stem cell transplantation to treat multiple sclerosis was published in the Lancet in 2016. He ran a clinical trial exploring the role of hematopoietic stem cell transplantation in preventing organ transplant rejection. He is a member of a BiocanRx funded\, pan-Canadian consortium to develop and improve the accessibility of new chimeric antigen receptor T lymphocytes for the treatment o
URL:https://bme.utoronto.ca/event/spotlight-on-clinical-translation-making-the-leap-from-the-lab-bench-to-phase-i-clinical-trials/
LOCATION:Virtual
CATEGORIES:Events & Workshops,External Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220609T160000
DTEND;TZID=America/Toronto:20220609T170000
DTSTAMP:20220606T140220Z
CREATED:20220606T140220Z
LAST-MODIFIED:20220606T140220Z
UID:10000029-1654790400-1654794000@bme.utoronto.ca
SUMMARY:Re-purposing imaging contrast agents for targeted cancer treatment - Princess Margaret Seminar Series
DESCRIPTION:Dr. Xiaohu Gao \nProfessor \nDepartment of Bioengineering and the Center for Nanotechnology \nUniversity of Washington| \n  \nPrincess Margaret Cancer Centre \nDr. Bob Bell Auditorium\, 6th Floor\, 6-604 \nJoin on MS Teams \n  \n*PLEASE NOTE: The seminar will be delivered live in-person at Princess Margaret Cancer Centre\, 6th floor Bob Bell Auditorium\, 610 University Ave and broadcasted via MS TEAMS.\nThose attending the in-person seminar must wear a mask and no food or drink will be permitted. All attendees must be fully vaccinated to enter the hospital. \n 
URL:https://bme.utoronto.ca/event/re-purposing-imaging-contrast-agents-for-targeted-cancer-treatment-princess-margaret-seminar-series/
CATEGORIES:External Speaker Series
END:VEVENT
END:VCALENDAR